Metabolism of the Novel IMP Dehydrogenase Inhibitor Benzamide Riboside

2002 ◽  
Vol 9 (7) ◽  
pp. 781-786 ◽  
Author(s):  
Walter Jager ◽  
Alexandra Salamon ◽  
Thomas Szekeres
2004 ◽  
Vol 1 (2) ◽  
pp. 225-229
Author(s):  
Walter Jager ◽  
Alexandra Salamon ◽  
Thomas Szekeres

1998 ◽  
Vol 42 (12) ◽  
pp. 3285-3289 ◽  
Author(s):  
Johan Neyts ◽  
Graciela Andrei ◽  
Erik De Clercq

ABSTRACT Mycophenolate mofetil (MMF) has been approved as an immunosuppressive agent in kidney transplant recipients and may thus be used concomitantly with antiherpetic agents, which are used for the treatment of intercurrent herpesvirus infections. We have recently demonstrated that MMF and its parent compound mycophenolic acid (MPA), which is a potent inhibitor of IMP dehydrogenase, potentiate the antiherpesvirus activity of acyclovir, ganciclovir, and penciclovir. We have now evaluated the antiviral efficacy of the combination of MPA and the novel antiherpesvirus agent H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine]. When combined with H2G, MPA (at concentrations ranging from 0.25 to 10 μg/ml, which are readily attainable in human plasma) markedly potentiated the antiviral efficacy of H2G against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), as reflected by a 10- to 150-fold decrease in the 50% effective concentration. Moreover, the activity of H2G against a thymidine kinase-deficient strain of HSV-1 (TK− HSV-1) was increased more than 2,500-fold when combined with MPA. MPA by itself had little or no effect on the replication of these viruses. Similar observations were made for varicella-zoster virus. Also, ribavirin (another inhibitor of IMP dehydrogenase) caused a marked enhancement of the activity of H2G against HSV-1 (10-fold), HSV-2 (10-fold), and TK− HSV-1 (>185-fold). Exogenously added guanosine reversed the potentiating effects of MPA on the antiviral activity of H2G, indicating that this potentiating effect resulted from a depletion of the endogenous dGTP pools, thus favoring the inhibitory action of the H2G triphosphate on the viral DNA polymerase.


1992 ◽  
Vol 186 (3) ◽  
pp. 1600-1606 ◽  
Author(s):  
Hiremagalur N. Jayaram ◽  
Kamran Gharehbaghi ◽  
Nagesh H. Jayaram ◽  
Jason Rieser ◽  
Karsten Krohn ◽  
...  

2004 ◽  
Vol 67 (1) ◽  
pp. 273-279 ◽  
Author(s):  
Vijaya L. Damaraju ◽  
Frank Visser ◽  
Jing Zhang ◽  
Delores Mowles ◽  
Amy M. L. Ng ◽  
...  

1992 ◽  
Vol 287 (3) ◽  
pp. 785-790 ◽  
Author(s):  
J Balzarini ◽  
E De Clercq

A rapid and convenient method has been developed to monitor the inhibition of inosinate (IMP) dehydrogenase by antimetabolites in intact human CEM lymphocytes. This method is based on the determination of 3H release from [2,8-3H]hypoxanthine ([2,8-3H]Hx) or [2,8-3H]inosine ([2,8-3H]Ino). The validity of this procedure was assessed by evaluating IMP dehydrogenase inhibition in intact CEM cells by the well-known IMP dehydrogenase inhibitors ribavirin, mycophenolic acid and tiazofurin. As reference materials, several compounds that are targeted at other enzymes in de novo purine nucleotide anabolism (i.e. hadacidine, acivicin) or catabolism (i.e. 8-aminoguanosine, allopurinol) were evaluated. There was a strong correlation between the inhibitory effects of the IMP dehydrogenase inhibitors (ribavirin, mycophenolic acid, tiazofurin) on 3H release from [2,8-3H]Hx and [2,8-3H]Ino in intact CEM cells and their ability to decrease intracellular GTP pool levels. The other compounds (hadacidine, acivicin, 8-aminoguanosine, allopurinol) had no marked effect on 3H release from [2,8-3H]Hx. Using this method, we demonstrated that the novel ribavirin analogue, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, is a potent inhibitor of IMP dehydrogenase in intact cells.


1994 ◽  
Vol 48 (7) ◽  
pp. 1413-1419 ◽  
Author(s):  
Kamran Gharehbaghi ◽  
Ajay Sreenath ◽  
Zhang Hao ◽  
Kenneth D. Paull ◽  
Thomas Szekeres ◽  
...  

2002 ◽  
Vol 9 (7) ◽  
pp. 743-748 ◽  
Author(s):  
Kamran Gharehbaghi ◽  
Werner Grunberger ◽  
Hiremagalur Jayaram

1994 ◽  
Vol 56 (6) ◽  
pp. 892-899 ◽  
Author(s):  
Kamran Gharehbaghi ◽  
Kenneth D. Paull ◽  
James A. Kelley ◽  
Joseph J. Barchi ◽  
Victor E. Marquez ◽  
...  

Life Sciences ◽  
2001 ◽  
Vol 69 (21) ◽  
pp. 2489-2502 ◽  
Author(s):  
Alexandra Salamon ◽  
Birgit Hagenauer ◽  
Therese Thalhammer ◽  
Thomas Szekeres ◽  
Karsten Krohn ◽  
...  

2010 ◽  
Vol 34 (8) ◽  
pp. S33-S33
Author(s):  
Wenchao Ou ◽  
Haifeng Chen ◽  
Yun Zhong ◽  
Benrong Liu ◽  
Keji Chen

Sign in / Sign up

Export Citation Format

Share Document